Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion

Journal of Hepatology

Volumn 62, Issue 4, 2015, Pages 848-854

  Poté, Nicolas ^a,b   Cauchy, François ^a,b   Albuquerque, Miguel ^a   Voitot, Hélène ^a   Belghiti, Jacques ^a   Castera, Laurent ^a   Puy, Hervé ^a,b   Bedossa, Pierre ^a,b   Paradis, Valérie ^a,b  

^a BEAUJON HOSPITAL   (France)

^b CENTRE DE RECHERCHE SUR L INFLAMMATION   (France)

Author keywords

Alpha fetoprotein; Diagnosis; Hepatocellular carcinoma; Microvascular invasion; Prothrombin induced by vitamin K absence II

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DECARBOXYPROTHROMBIN; BIOLOGICAL MARKER; PROTEIN PRECURSOR; PROTHROMBIN; TUMOR MARKER;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER PROGNOSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTHROMBIN TIME; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT; TUMOR VOLUME; AGED; BLOOD; CASE CONTROL STUDY; COMPARATIVE EFFECTIVENESS; DIAGNOSIS; EARLY DIAGNOSIS; FRANCE; LIVER TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; TUMOR INVASION;

ADULT; AGED; ALPHA-FETOPROTEINS; BIOMARKERS; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; COMPARATIVE EFFECTIVENESS RESEARCH; EARLY DETECTION OF CANCER; FEMALE; FRANCE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN PRECURSORS; PROTHROMBIN; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84926415936     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.11.005     Document Type: Article

References (37)

1. S.F. Altekruse, K.A. McGlynn, and M.E. Reichman Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005 J Clin Oncol 27 2009 1485 1491
2. J.M. Llovet, A. Burroughs, and J. Bruix Hepatocellular carcinoma Lancet 362 2003 1907 1917
3. J.M. Llovet, and J. Bruix Novel advancements in the management of hepatocellular carcinoma in 2008 J Hepatol 48 2008 S20 S37
4. S. Arii, Y. Yamaoka, S. Futagawa, K. Inoue, K. Kobayashi, and M. Kojiro Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan Hepatology 32 2000 1224 1229
5. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma J Hepatol 56 2012 908 943
6. A. Singal, M.L. Volk, A. Waljee, R. Salgia, P. Higgins, and M. Rogers Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis Aliment Pharmacol Ther 30 2009 37 47
7. C. Li, Z. Zhang, P. Zhang, and J. Liu Diagnostic accuracy of des-gamma-carboxy prothrombin versus α-fetoprotein for hepatocellular carcinoma: a systematic review Hepatol Res 44 2014 E11 E25
8. H.A. Liebman, B.C. Furie, M.J. Tong, R.A. Blanchard, K.J. Lo, and S.D. Lee Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma N Engl J Med 310 1984 1427 1431
9. S.L. Tsai, G.T. Huang, P.M. Yang, J.C. Sheu, J.L. Sung, and D.S. Chen Plasma des-gamma-carboxyprothrombin in the early stage of hepatocellular carcinoma Hepatology 11 1990 481 488
10. Y. Inagaki, H.L. Xu, K. Hasegawa, T. Aoki, Y. Beck, and Y. Sugawara Des-gamma-carboxyprothrombin in patients with hepatocellular carcinoma and liver cirrhosis J Dig Dis 12 2011 481 488
11. M. Kudo, N. Izumi, N. Kokudo, O. Matsui, M. Sakamoto, and O. Nakashima Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version Dig Dis 29 2011 339 364
12. K. Shirabe, S. Itoh, T. Yoshizumi, Y. Soejima, A. Taketomi, and S.-I. Aishima The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin J Surg Oncol 95 2007 235 240
13. S. Eguchi, M. Takatsuki, M. Hidaka, A. Soyama, T. Tomonaga, and I. Muraoka Predictor for histological microvascular invasion of hepatocellular carcinoma: a lesson from 229 consecutive cases of curative liver resection World J Surg 34 2010 1034 1038
14. M. Kaibori, M. Ishizaki, K. Matsui, and A.-H. Kwon Predictors of microvascular invasion before hepatectomy for hepatocellular carcinoma J Surg Oncol 102 2010 462 468
15. Y. Yamashita, E. Tsuijita, K. Takeishi, M. Fujiwara, S. Kira, and M. Mori Predictors for microinvasion of small hepatocellular carcinoma ≤2 cm Ann Surg Oncol 19 2012 2027 2034
16. Y. Harino, M. Fujii, S. Imura, Y. Morine, T. Ikemoto, and Y. Soejima The role of des-gamma-carboxyprothrombin expression in hepatocellular carcinoma Hepatogastroenterology 55 2008 1385 1389
17. S. Jonas, W.O. Bechstein, T. Steinmüller, M. Herrmann, C. Radke, and T. Berg Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis Hepatology 33 2001 1080 1086
18. S. Sumie, R. Kuromatsu, K. Okuda, E. Ando, A. Takata, and N. Fukushima Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors Ann Surg Oncol 15 2008 1375 1382
19. H. Imamura, Y. Matsuyama, E. Tanaka, T. Ohkubo, K. Hasegawa, and S. Miyagawa Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy J Hepatol 38 2003 200 207
20. M. Rodríguez-Perálvarez, T.V. Luong, L. Andreana, T. Meyer, A.P. Dhillon, and A.K. Burroughs A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability Ann Surg Oncol 20 2013 325 339
21. J.M. Llovet, C. Brú, and J. Bruix Prognosis of hepatocellular carcinoma: the BCLC staging classification Semin Liver Dis 19 1999 329 338
22. International Consensus Group for Hepatocellular NeoplasiaThe International Consensus Group for Hepatocellular Neoplasia Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia Hepatology 49 2009 658 664
23. J.M. Ertle, D. Heider, M. Wichert, B. Keller, R. Kueper, and P. Hilgard A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma Digestion 87 2013 121 131
24. H.B. El-Serag Hepatocellular carcinoma N Engl J Med 365 2011 1118 1127
25. J.A. Marrero, G.L. Su, W. Wei, D. Emick, H.S. Conjeevaram, and R.J. Fontana Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients Hepatology 37 2003 1114 1121
26. F.A. Durazo, L.M. Blatt, W.G. Corey, J.-H. Lin, S. Han, and S. Saab Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma J Gastroenterol Hepatol 23 2008 1541 1548
27. A.S. Lok, R.K. Sterling, J.E. Everhart, E.C. Wright, J.C. Hoefs, and A.M. Di Bisceglie Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma Gastroenterology 138 2010 493 502
28. J.A. Marrero, Z. Feng, Y. Wang, M.H. Nguyen, A.S. Befeler, and L.R. Roberts Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma Gastroenterology 137 2009 110 118
29. M. Tamano, H. Sugaya, M. Oguma, M. Iijima, M. Yoneda, and T. Murohisa Serum and tissue PIVKA-II expression reflect the biological malignant potential of small hepatocellular carcinoma Hepatol Res 22 2002 261 269
30. W. Tang, N. Kokudo, Y. Sugawara, Q. Guo, H. Imamura, and K. Sano Des-gamma-carboxyprothrombin expression in cancer and/or non-cancer liver tissues: association with survival of patients with resectable hepatocellular carcinoma Oncol Rep 13 2005 25 30
31. T. Fujikawa, H. Shiraha, N. Ueda, N. Takaoka, Y. Nakanishi, and N. Matsuo Des-gamma-carboxyl prothrombin-promoted vascular endothelial cell proliferation and migration J Biol Chem 282 2007 8741 8748
32. S.-B. Wang, Y.-N. Cheng, S.-X. Cui, J.L. Zhong, S.G. Ward, and L.-R. Sun Des-gamma-carboxy prothrombin stimulates human vascular endothelial cell growth and migration Clin Exp Metastasis 26 2009 469 477
33. F.-J. Gao, S.-X. Cui, M.-H. Chen, Y.-N. Cheng, L.-R. Sun, and S.G. Ward Des-gamma-carboxy prothrombin increases the expression of angiogenic factors in human hepatocellular carcinoma cells Life Sci 83 2008 815 820
34. A. Villanueva, Y. Hoshida, C. Battiston, V. Tovar, D. Sia, and C. Alsinet Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma Gastroenterology 140 2011 1501 1512
35. B. Mínguez, Y. Hoshida, A. Villanueva, S. Toffanin, L. Cabellos, and S. Thung Gene-expression signature of vascular invasion in hepatocellular carcinoma J Hepatol 55 2011 1325 1331
36. J.-C. Nault, A. De Reyniès, A. Villanueva, J. Calderaro, S. Rebouissou, and G. Couchy A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection Gastroenterology 145 2013 176 187
37. N. Poté, T. Alexandrov, J. Le Faouder, S. Laouirem, T. Léger, and M. Mebarki Imaging mass spectrometry reveals modified forms of histone H4 as new biomarkers of microvascular invasion in hepatocellular carcinomas Hepatology 58 2013 983 994